记忆T细胞在直肠癌术前放化疗与免疫治疗衔接中的潜力
本小型综述讨论局部晚期直肠癌中全直肠系膜切除与术前放疗的关键作用,并基于正在进行的II-III期IG/IMRT-SIB试验中发现循环髓源性抑制细胞与中枢记忆CD8+ T细胞比值急剧升高,提出恢复CD45RO记忆T细胞池可作为整合辅助干预的一部分,并讨论改良IL-2与二甲双胍的免疫纠正潜力。
要点
- 全直肠系膜切除与术前放疗对局部晚期直肠癌的临床结局至关重要。
- 在IG/IMRT-SIB试验框架下观察到循环髓源性抑制细胞与中枢记忆CD8+ T细胞比值急剧升高。
- 恢复CD45RO记忆T细胞池可能是整合辅助干预的一部分。
核心结论
- 循环髓源性抑制细胞与中枢记忆CD8+ T细胞比值急剧升高可能是肿瘤免疫逃逸和播散的机制,恢复CD45RO记忆T细胞池可能是整合辅助干预的一部分。
研究设计与样本
- 小型综述,未报告系统检索范围与样本量。
主要发现
- 在正在进行的II-III期IG/IMRT-SIB试验框架下观察到循环(促肿瘤)髓源性抑制细胞与(抗肿瘤)中枢记忆CD8+ T细胞比值急剧升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The management of locally advanced rectal cancer has passed a long way of developments, where total mesorectal excision and preoperative radiotherapy are crucial to secure clinical outcome. These and other aspects of multidisciplinary strategies are in-depth summarized in the literature, while our mini-review pursues a different goal. From an ethical and medical standpoint, we witness a delayed implementation of novel therapies given the cost/time consuming process of organizing randomized trials that would bridge an already excellent local control in cT3-4 node-positive disease with long-term survival. This unfortunate separation of clinical research and medical care provides a strong motivation to repurpose known pharmaceuticals that suit for treatment intensification with a focus on distant control. In the framework of on-going phase II-III IG/IMRT-SIB trials, we came across an intriguing translational observation that the ratio of circulating (protumor) myeloid-derived suppressor cells to (antitumor) central memory CD8+ T cells is drastically increased, a possible mechanism of tumor immuno-escape and spread. This finding prompts that restoring the CD45RO memory T-cell pool could be a part of integrated adjuvant interventions. Therefore, the immunocorrective potentials of modified IL-2 and the anti-diabetic drug metformin are thoroughly discussed in the context of tumor immunobiology, mTOR pathways and revised Warburg effect.
引用
- de Mey S, Jiang H, Wang H, et al. Potential of memory T cells in bridging preoperative chemoradiation and immunotherapy in rectal cancer. Radiother Oncol. 2018. PMID: 29871814. doi:10.1016/j.radonc.2018.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。